View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 26, 2020

WHO halts hydroxychloroquine Covid-19 trial over safety concerns

The World Health Organization (WHO) has temporarily suspended a clinical trial of the malaria drug hydroxychloroquine in Covid-19 patients over safety concerns, according to the organisation’s director-general Dr Tedros Adhanom Ghebreyesus.

The move comes after data from an observational study published in The Lancet journal revealed a higher mortality rate in patients treated with hydroxycholoroquine when given alone or with a macrolide.

During the observational study, hydroxychloroquine and chloroquine were assessed for their effects on hospitalised Covid-19 patients.

Read more here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena